Pneumococcal Vaccination for Children
<p id="p1"><em><italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">Streptococcus pneumoniae</italic></em> is a common cause of noninvasive as well as serious invasive infections in children. Two class...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2025
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/89785 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | <p id="p1"><em><italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">Streptococcus pneumoniae</italic></em> is a common cause of noninvasive as well as serious invasive infections in children. Two classes of pneumococcal vaccines are currently available for use in children: the Pneumococcal Conjugate Vaccine (PCV) and the 23-valent Pneumococcal Polysaccharide Vaccine (PPSV-23). PCV is licensed for use in individuals 6 weeks of age and older, and its inclusion in National Immunization Programs is important for reducing the burden of pneumococcal diseases. PPSV-23 is licensed for use in children above 2 years and adults, and it is recommended only for individuals at increased risk of severe pneumococcal diseases. In order to expand the serotype coverage, efficacy, and effectiveness, newer pneumococcal vaccines are undergoing different phases of clinical trials. This chapter aims to discuss the serotypes responsible for pneumococcal diseases (PDs) and the pneumococcal vaccines, licensed and under trial in the world, used for prevention of PDs.</p> |
|---|---|
| ISBN: | 978-1-83768-080-1 |
| DOI: | 10.5772/intechopen.115612 |